The clinical significance of CXCL5 in non-small cell lung cancer

被引:36
作者
Wu, Kongju [1 ]
Yu, Shengnan [2 ]
Liu, Qian [2 ]
Bai, Xianguang [1 ]
Zheng, Xinhua [1 ]
Wu, Kongming [2 ]
机构
[1] Pingdingshan Univ, Med Sch, Pingdingshan, Henan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, 1095 Jiefang, Wuhan 430030, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
non-small cell lung cancer; chemokine; CXCL5; migration; prognosis; MESENCHYMAL TRANSITION; ADJUVANT CHEMOTHERAPY; PROGNOSTIC MARKER; GENE SIGNATURE; EARLY-STAGE; EXPRESSION; SURVIVAL; PREDICTION; ADENOCARCINOMA; INVASION;
D O I
10.2147/OTT.S148772
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
As a CXC-type chemokine, ENA78/CXCL5 is an important attractant for granulocytes by binding to its receptor CXCR2. Recent studies proved that CXCL5/CXCR2 axis plays an oncogenic role in many human cancers. However, the exact clinical significance of CXCL5 in lung cancer has not been well defined. Here, we found that the serum protein expression of CXCL5 was significantly increased in non-small cell lung cancer (NSCLC) compared with that in healthy volunteers. Immunohistochemistry staining revealed that CXCL5 protein was higher in various lung cancer tissues compared with normal tissues. Moreover, CXCL5 expression correlated with histological grade, tumor size, and TNM stage in NSCLC. Elevated CXCL5 protein abundance predicted poor overall survival in adenocarcinoma patients. Further meta-analysis demonstrated that CXCL5 mRNA expression was also positively associated with tumor stage, lymph node metastasis, and worse survival. Kaplan-Meier plot analyses indicated high CXCL5 was associated with short overall survival and progression-free survival. Together, these results indicated that CXCL5 may be a potential biomarker for NSCLC.
引用
收藏
页码:5561 / 5573
页数:13
相关论文
共 60 条
[1]  
[Anonymous], CAARRAY MEYER 00191
[2]  
[Anonymous], TUMOUR BIOL
[3]  
[Anonymous], [No title captured]
[4]  
[Anonymous], SCI REP UK
[5]   Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer [J].
Arenberg, DA ;
Keane, MP ;
DiGiovine, B ;
Kunkel, SL ;
Morris, SB ;
Xue, YY ;
Burdick, MD ;
Glass, MC ;
Iannettoni, MD ;
Strieter, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03) :465-472
[6]   Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Non-Small Cell Lung Cancer [J].
Baty, Florent ;
Facompre, Michael ;
Kaiser, Sergio ;
Schumacher, Martin ;
Pless, Miklos ;
Bubenclorf, Lukas ;
Savic, Spasenija ;
Marrer, Estelle ;
Budach, Wolfgang ;
Buess, Martin ;
Kehren, Jeanne ;
Tamm, Michael ;
Brutsche, Martin H. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (02) :181-188
[7]   Gene-expression profiles predict survival of patients with lung adenocarcinoma [J].
Beer, DG ;
Kardia, SLR ;
Huang, CC ;
Giordano, TJ ;
Levin, AM ;
Misek, DE ;
Lin, L ;
Chen, GA ;
Gharib, TG ;
Thomas, DG ;
Lizyness, ML ;
Kuick, R ;
Hayasaka, S ;
Taylor, JMG ;
Iannettoni, MD ;
Orringer, MB ;
Hanash, S .
NATURE MEDICINE, 2002, 8 (08) :816-824
[8]   Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].
Bild, AH ;
Yao, G ;
Chang, JT ;
Wang, QL ;
Potti, A ;
Chasse, D ;
Joshi, MB ;
Harpole, D ;
Lancaster, JM ;
Berchuck, A ;
Olson, JA ;
Marks, JR ;
Dressman, HK ;
West, M ;
Nevins, JR .
NATURE, 2006, 439 (7074) :353-357
[9]   Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation [J].
Botling, Johan ;
Edlund, Karolina ;
Lohr, Miriam ;
Hellwig, Birte ;
Holmberg, Lars ;
Lambe, Mats ;
Berglund, Anders ;
Ekman, Simon ;
Bergqvist, Michael ;
Ponten, Fredrik ;
Koenig, Andre ;
Fernandes, Oswaldo ;
Karlsson, Mats ;
Helenius, Gisela ;
Karlsson, Christina ;
Rahnenfuehrer, Joerg ;
Hengstler, Jan G. ;
Micke, Patrick .
CLINICAL CANCER RESEARCH, 2013, 19 (01) :194-204
[10]   Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients [J].
Der, Sandy D. ;
Sykes, Jenna ;
Pintilie, Melania ;
Zhu, Chang-Qi ;
Strumpf, Dan ;
Liu, Ni ;
Jurisica, Igor ;
Shepherd, Frances A. ;
Tsao, Ming-Sound .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) :59-64